Suven Life gets drug patents in Russia, Australia

New Delhi, May 27 (UNI) Drug firm Suven Life Sciences Ltd today said it has received two product patents in Russia and Australia for two of its new chemical entities (NCEs) used in the treatment of disorders associated with neuro-degenerative diseases.

The company said in a statement that the patents for the drug candidates, which target 18-billion-dollar potential market globally, are valid till 2023.

UNI SG ARB DS1328